ArticleCancers2022

TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy.

Jiangyong Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.